TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35306524

Group type: EXPERIMENTAL
Intervention: Electrophysiological stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid administration
Number of subjects: 0
Study: 35306553

Group type: EXPERIMENTAL
Intervention: Mesalazine ≥4 g/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Mesalazine treatment duration >6 months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Mesalazine treatment duration 3-6 months
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Mesalazine treatment
Number of subjects: 151
Study: 35306594

Group type: EXPERIMENTAL
Intervention: Sinovac-CoronaVac vaccine (two doses 28 days apart, D0/D28)
Number of subjects: 51
Study: 35307611

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 1)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 2)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily in continuous 21-day cycles
Number of subjects: 109
Study: 35307761

Group type: EXPERIMENTAL
Intervention: Dietary pattern 1 (high in discretionary foods and saturated fatty acids, low in fibre)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Dietary pattern 2 (positively correlated with discretionary foods and SFA)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Dietary pattern 3 (positively correlated with SFA and fibre)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: FTO risk genotype
Number of subjects: 1280
Study: 35307972

Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib (DL1: avelumab 10 mg/kg IV q2weeks, axitinib 3 mg po bid, palbociclib 75 mg po daily for 7 days off/21 days on)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib (DL1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Avelumab, axitinib, and palbociclib combination
Number of subjects: 15
Study: 35308034

Group type: EXPERIMENTAL
Intervention: 200 mL of convalescent plasma (Low-volume)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 400 mL of convalescent plasma (High-volume)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 129
Study: 35308099

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) prophylaxis administered intravenously for up to 104 weeks, every 7 days, twice weekly, or three times weekly.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol) prophylaxis
Number of subjects: 160
Study: 35308376

Group type: EXPERIMENTAL
Intervention: 3HP treatment (once-weekly rifapentine plus isoniazid for 3 months)
Number of subjects: 80
Study: 35308535

Group type: EXPERIMENTAL
Intervention: 2 × 40 mg intravenous dexamethasone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 35308563

Group type: EXPERIMENTAL
Intervention: EEG-based intervention (MAP intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG-based intervention (MAC intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG-based intervention (combined MAP/MAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EEG-blinded standard anaesthesia (control)
Number of subjects: 0
Study: 35309052

Group type: EXPERIMENTAL
Intervention: 3-min active stand (AS) with Finapres
Number of subjects: 0
Study: 35309087

Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg plus palbociclib 125 mg
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg plus palbociclib 125 mg
Number of subjects: 1066
Study: 35309363

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 110
Study: 35309551

Group type: EXPERIMENTAL
Intervention: Brush-sign present
Number of subjects: 504

Group type: COMPARATOR
Intervention: No brush-sign
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Brush-sign
Number of subjects: 504
Study: 35310101

Group type: EXPERIMENTAL
Intervention: Candidate intervention components including sleep restriction, stimulus control, and systematic bright light exposure.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Candidate intervention components (various combinations) in a full factorial design.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 95
Study: 35310526

Group type: EXPERIMENTAL
Intervention: Allopregnanolone (ALLO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 35310617

Group type: EXPERIMENTAL
Intervention: Policy, systems, and environmental (PSE) changes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Community engagement
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Historical trauma and tribal politics
Number of subjects: 46
Study: 35310961

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) after starting systemic immune checkpoint-based combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued systemic therapy (control group)
Number of subjects: 0
Study: 35310981

Group type: EXPERIMENTAL
Intervention: Moderate or severe mitral regurgitation (MR)
Number of subjects: 28358

Group type: COMPARATOR
Intervention: Heart failure (HF)
Number of subjects: 28358

Group type: COMPARATOR
Intervention: Non-heart failure (non-HF)
Number of subjects: 28358
Study: 35310985

Group type: EXPERIMENTAL
Intervention: CCC-ACS CS score
Number of subjects: 76807
Study: 35310997

Group type: EXPERIMENTAL
Intervention: LINAC-based stereotactic arrhythmia radioablation
Number of subjects: 5
Study: 35311345

Group type: EXPERIMENTAL
Intervention: Motor skill learning (MSkL) training using a neurorehabilitation robot over 3 consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Motor skill learning (MSkL) training using a neurorehabilitation robot
Number of subjects: 20
Study: 35311679

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 35313124

Group type: EXPERIMENTAL
Intervention: Opicapone
Number of subjects: 0
Study: 35313671

Group type: EXPERIMENTAL
Intervention: Frailty (dichotomous construct)
Number of subjects: 204
Study: 35313819

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (Fitbit InspireHR) used for 12 weeks with personalized activity goals and weekly feedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (Fitbit InspireHR)
Number of subjects: 40
Study: 35313956

Group type: EXPERIMENTAL
Intervention: MTX/ETA
Number of subjects: 65

Group type: COMPARATOR
Intervention: MTX/ADA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pooled data from ESPOIR and SATRAPE cohorts
Number of subjects: 65
Study: 35313957

Group type: EXPERIMENTAL
Intervention: Eye Tracking (ET) tasks including Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks
Number of subjects: 399

Group type: COMPARATOR
Intervention: Eye Tracking (ET) tasks
Number of subjects: 399
Study: 35313988

Group type: EXPERIMENTAL
Intervention: Motor control exercise program (three 40-min sessions per week from < 20 weeks until 34-36 weeks of gestation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motor control exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard prenatal care + exercise program after 6 weeks postpartum
Number of subjects: 40
Study: 35314501

Group type: EXPERIMENTAL
Intervention: Simplified Edinburgh CT criteria
Number of subjects: 210
Study: 35314692

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 307

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 307
Study: 35314693

Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg, 5-days-on/2-days-off, plus letrozole or fulvestrant
Number of subjects: 54
Study: 35314708

Group type: EXPERIMENTAL
Intervention: Machine learning models using predictors from the dataset
Number of subjects: 697
Study: 35314720

Group type: EXPERIMENTAL
Intervention: EPI-CE (ExoDx Prostate IntelliScore) urine test
Number of subjects: 109
Study: 35314788

Group type: EXPERIMENTAL
Intervention: Periodic fasting mimicking diet (FMD), low in calories, sugars, and proteins but high in unsaturated fats, for 4 consecutive days, repeated in cycles over 3 months.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Periodic fasting mimicking diet (FMD)
Number of subjects: 29
Study: 35314842

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 40
Study: 35314843

Group type: EXPERIMENTAL
Intervention: TGF-β-resistant CAR T cells
Number of subjects: 18
Study: 35315341

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic strategies targeting exosomal crosstalk
Number of subjects: 0
Study: 35315588

Group type: EXPERIMENTAL
Intervention: Incident sleep disturbance in breast cancer survivors (10%)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Incident sleep disturbance in noncancer controls (13.5%)
Number of subjects: 400
Study: 35315601

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 3 years in idiopathic GHD patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 3 years in organic GHD patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 3 years in both idiopathic and organic GHD patients
Number of subjects: 163
Study: 35315687

Group type: EXPERIMENTAL
Intervention: Temsavir coadministered with Cobicistat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsavir coadministered with Etravirine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsavir coadministered with Darunavir/Cobicistat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsavir coadministered with Darunavir/Ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsavir with or without Etravirine
Number of subjects: 0
Study: 35315780

Group type: EXPERIMENTAL
Intervention: Nintendo Ring Fit Adventure (RFA) intervention, 30 minutes 3 times per week for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (maintained regular habits)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nintendo Ring Fit Adventure (RFA) intervention
Number of subjects: 80
Study: 35315783

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment protocol (20 treatments over 4 weeks) with an intensity of 120% of resting motor threshold, frequency of 10 Hz, 10 trains of 60 pulses per train (total of 600 pulses), intertrain interval of 45 seconds.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham rTMS protocol (control group).
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment.
Number of subjects: 44
Study: 35315785

Group type: EXPERIMENTAL
Intervention: VR balance exergames using a movement recognition-based system (MindMotion GO; MindMaze SA) for 3 weeks (MS) and 4 weeks (stroke)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale scores
Number of subjects: 81
Study: 35316212

Group type: EXPERIMENTAL
Intervention: Cycling exercise for 12 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 11
Study: 35316227

Group type: EXPERIMENTAL
Intervention: Various pharmacological interventions including antivirals, antimalarials, corticosteroids, NSAIDs, and antipyretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (Pfizer/BioNTech and mRNA-1273 Moderna)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO and CDC guidelines for managing adverse effects
Number of subjects: 0
Study: 35316328

Group type: EXPERIMENTAL
Intervention: Nivolumab alone (240 mg every 2 weeks for up to 6 cycles)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nivolumab + NICE (ifosfamide, carboplatin, etoposide) for 2 cycles after nivolumab
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nivolumab alone or in combination with NICE
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All treated patients (n = 43)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients who bridged directly to AHCT (n = 33)
Number of subjects: 43
Study: 35316572

Group type: EXPERIMENTAL
Intervention: Severe cachexia (SC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cachexia (general)
Number of subjects: 45
Study: 35316771

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo confocal microscopy (EVCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Confocal laser endomicroscopy (CLE) and ex vivo confocal microscopy (EVCM)
Number of subjects: 0
Study: 35316922

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 or 150 mg every 2 weeks for ≥ 3 to ≤ 30 months
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alirocumab with concomitant high-intensity statins
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alirocumab with moderate/low-intensity statins
Number of subjects: 994

Group type: COMPARATOR
Intervention: Alirocumab with no statin
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alirocumab with prior ezetimibe
Number of subjects: 994

Group type: COMPARATOR
Intervention: Alirocumab without prior ezetimibe
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alirocumab with high-intensity statins
Number of subjects: 994
Study: 35317413

Group type: EXPERIMENTAL
Intervention: Tablet-based Tanzania 24-hour recall tool (TZ-24hr-DR)
Number of subjects: 0
Study: 35317612

Group type: EXPERIMENTAL
Intervention: Modified Herniation WFNS Scale (hWFNS)
Number of subjects: 250

Group type: COMPARATOR
Intervention: World Federation of Neurosurgical Societies (WFNS) Scale
Number of subjects: 250
Study: 35317851

Group type: EXPERIMENTAL
Intervention: SCONE™ therapy (transcutaneous spinal cord neuromodulation)
Number of subjects: 0
Study: 35318970

Group type: EXPERIMENTAL
Intervention: Gadopiclenol at a dose of 0.05 mmol/kg
Number of subjects: 80
Study: 35319468

Group type: EXPERIMENTAL
Intervention: Wakey! app
Number of subjects: 5413
Study: 35319467

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (aerobic and resistance training, 3 to 5 times a week for 12 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Counseling session on healthy eating with a dietitian
Number of subjects: 40
Study: 35319502

Group type: EXPERIMENTAL
Intervention: CYP2D6 testing
Number of subjects: 2436654

Group type: COMPARATOR
Intervention: Opioids coprescribed with antidepressants interacting with CYP2D6
Number of subjects: 2436654

Group type: EXPERIMENTAL
Intervention: Predicted phenotypes and drug-drug interactions
Number of subjects: 2436654
Study: 35319535

Group type: EXPERIMENTAL
Intervention: Real-time video Pediatric Gait, Arms, Legs, and Spine (v-pGALS) assessment
Number of subjects: 20
Study: 35319751

Group type: EXPERIMENTAL
Intervention: α-mFAPxCD40
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouse anti-CD40
Number of subjects: 0
Study: 35320340

Group type: EXPERIMENTAL
Intervention: GO-EXCAP intervention (mobile health exercise intervention)
Number of subjects: 25
Study: 35320424

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 95
Study: 35320489

Group type: EXPERIMENTAL
Intervention: Bariatric group (RYGB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsurgical group (control)
Number of subjects: 40
Study: 35320595

Group type: EXPERIMENTAL
Intervention: Digital behaviour change interventions (DBCIs) delivered by an oncology dietitian, including online food diaries and fortnightly telephone consultations.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evaluation form completion by participants.
Number of subjects: 20
Study: 35320878

Group type: EXPERIMENTAL
Intervention: Myosuit (robotic assistance) during activities of daily life (ADL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Myosuit (robotic assistance) during rehabilitation exercise unit (REU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No robotic assistance during activities of daily life (ADL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No robotic assistance during rehabilitation exercise unit (REU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acceptability of Myosuit
Number of subjects: 20
Study: 35321072

Group type: EXPERIMENTAL
Intervention: Sirius Robotic Flexible Endoscopic System
Number of subjects: 13
Study: 35321427

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (125 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (100 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (125 mg), Pyrotinib (320 mg), Letrozole (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Study treatment (1L HER2-targeted therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Study treatment (2L HER2-targeted therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Study treatment (2L setting)
Number of subjects: 15
Study: 35321501

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 35321652

Group type: EXPERIMENTAL
Intervention: Statin users (n=87)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-users of statins (n=87)
Number of subjects: 174
Study: 35321744

Group type: EXPERIMENTAL
Intervention: Somatocognitive therapy (SCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard PVD treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tampon test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tampon tests
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 14-day diary
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall feasibility outcomes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 10
Study: 35321895

Group type: EXPERIMENTAL
Intervention: Pfizer BNT162b2 mRNA COVID-19 vaccine, 1 dose, administered within 4 days of enrolment
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Control group (unvaccinated or vaccinated later)
Number of subjects: 1504
Study: 35321900

Group type: EXPERIMENTAL
Intervention: multibranched, off-the-shelf endograft (Guo's renovisceral artery reconstruction-1)
Number of subjects: 73
Study: 35321941

Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Physiotherapist's confidence in clinical diagnosis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis involving non-parenchymal conditions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clinical signs reflecting abolished lung ventilation
Number of subjects: 151
Study: 35321997

Group type: EXPERIMENTAL
Intervention: Normoestimators (TST estimation <±60 minutes)
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Underestimators (TST underestimation ≥60 minutes)
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Overestimators (TST overestimation ≥60 minutes)
Number of subjects: 2540

Group type: EXPERIMENTAL
Intervention: Absolute value of SOD in TST
Number of subjects: 2540
Study: 35322185

Group type: EXPERIMENTAL
Intervention: Biallelic pathogenic variants in SBDS
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: SBDS c.258 + 2T > C and c.183_184TA > CT genotypes
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pancreatic insufficiency
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bony abnormalities
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Developmental delay
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Risk of hematologic malignancies
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Risk of solid malignancies
Number of subjects: 47
Study: 35322287

Group type: EXPERIMENTAL
Intervention: Copanlisib 60 mg intravenous infusion on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 16
Study: 35322330

Group type: EXPERIMENTAL
Intervention: Contact Force (CF) during RF ablation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Contact Force (CF) > 25 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) delivery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoroscopy time during procedure
Number of subjects: 45
Study: 35322504

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the nucleus accumbens or subcallosal cingulate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 8
Study: 35322535

Group type: EXPERIMENTAL
Intervention: Ready-to-use room temperature liquid stable formulation of glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lyophilised formulation of glucagon
Number of subjects: 0
Study: 35322553

Group type: EXPERIMENTAL
Intervention: H19 siRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-29b antagomir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1QTNF6 overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-29b
Number of subjects: 0
Study: 35322677

Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Number of subjects: 102
Study: 35323030

Group type: EXPERIMENTAL
Intervention: Intensively monitored antiretroviral pause (IMAP)
Number of subjects: 29
Study: 35323116

Group type: EXPERIMENTAL
Intervention: Serious game intervention for smoking cessation (details not provided)
Number of subjects: 473
Study: 35323121

Group type: EXPERIMENTAL
Intervention: SurgeCon intervention (protocol-driven software platform, restructured ED organization and workflow)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: SurgeCon intervention
Number of subjects: 570
Study: 35323125

Group type: EXPERIMENTAL
Intervention: Diagnostic Decision Support System (DDSS) prototype
Number of subjects: 20
Study: 35323379

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST) with intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training (CBSST) with placebo
Number of subjects: 0
Study: 35323885

Group type: EXPERIMENTAL
Intervention: Educational intervention (oral and written education about LB)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (remaining general practices in Funen)
Number of subjects: 196